Ablavar
Loading...Ablavar Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
ABLAVAR is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease [see Clinical Studies (14)].
History
There is currently no drug history available for this drug.
Other Information
ABLAVAR (gadofosveset trisodium) Injection is a sterile, nonpyrogenic, formulation of a stable gadolinium diethylenetriaminepentaacetic acid (GdDTPA) chelate derivative with a diphenylcyclohexylphosphate group. Each mL of ABLAVAR Injection contains 244 mg of gadofosveset trisodium (0.25 mmol), 0.268 mg of fosveset, and water for injection.
It contains no preservative and the solution pH ranges between 6.5 and 8.0.
Gadofosveset trisodium is chemically trisodium-{(2-(R)-[(4,4-diphenylcyclohexyl) phosphonooxymethyl]-diethylenetriaminepentaacetato)(aquo) gadolinium(III),with a molecular weight of 975.88 g/mol, and an empirical formula of C33H40GdN3Na3O15P. It has a structural formula:
Pertinent physiochemical data of ABLAVAR Injection are provided below:
| Parameter | Condition | Value |
| Osmolality (mOsmol/kg water) | @ 37°C | 825 |
| Viscosity (cP) | @ 20°C | 3.0 |
| Density (g/mL) | @ 25°C | 1.1224 |
Sources
Ablavar Manufacturers
-
Lantheus Medical Imaging, Inc.
![Ablavar (Gadofosveset Trisodium) Injection, Solution [Lantheus Medical Imaging, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Ablavar | Lantheus Medical Imaging, Inc.
2.1 Dosing GuidelinesAdminister ABLAVAR as an intravenous bolus injection, manually or by power injection, at a dose of 0.12 mL/kg body weight (0.03 mmol/kg) over a period of time up to 30 seconds followed by a 25-30 mL normal saline flush. (See Table 1 for weight-adjusted dose volumes).
TABLE 1. Weight-Adjusted Volumes for the 0.03 mmol/kg Dose Body Weight Volume Kilograms (kg) Pounds (lb) Milliliters (mL) 40 88 4.8 50 110 6.0 60 132 7.2 70 154 8.4 80 176 9.6 90 198 10.8 100 220 12.0 110 242 13.2 120 264 14.4 130 286 15.6 140 308 16.8 150 330 18.0 160 352 19.2Inspect the ABLAVAR vial visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present.
ABLAVAR is intended for single use only and should be used immediately upon opening. Discard any unused portion of the ABLAVAR vial.
Do not mix intravenous medications or parenteral nutrition solutions with ABLAVAR. Do not administer any other medications in the same intravenous line simultaneously with ABLAVAR.
2.2 Imaging GuidelinesABLAVAR imaging is completed in two stages: the dynamic imaging stage and the steady-state imaging stage. Both stages are essential for adequate evaluation of the arterial system, and dynamic imaging always precedes steady-state imaging. During interpretation of the steady-state images, ABLAVAR within the venous system may limit or confound the detection of arterial lesions.
To assess the initial distribution of ABLAVAR within the arterial system, begin dynamic imaging immediately upon injection. Begin steady state imaging after dynamic imaging has been completed, generally 5 to 7 minutes following ABLAVAR administration. At this time point, ABLAVAR is generally distributed throughout the blood. In clinical trials, steady-state imaging was completed within approximately one hour following ABLAVAR injection.
Login To Your Free Account